EZH2, despite of its ability to trimethylate lysine 27 in histone H3, when phosphorylated, suppressed its methyltransferase activity [46, 47], and switched to a coactivator for its oncogenic function in prostate cancer [48]. Here, EZH2 is linked to prostate cancer.